middle.news
Syntara Unveils Next Steps for Amsulostat in Investor Webinar
10:01am on Monday 11th of August, 2025 AEST
•
Healthcare
Read Story
Syntara Unveils Next Steps for Amsulostat in Investor Webinar
10:01am on Monday 11th of August, 2025 AEST
Key Points
Investor webinar scheduled for 11 August 2025
Amsulostat granted FDA Fast Track and Orphan Drug designations
Phase 1c/2 trial initiated for myelodysplastic syndrome
Combination studies with JAK inhibitors underway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE